deferiprone has been researched along with Cholera Infantum in 8 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In previous trials, the orally active iron chelator deferiprone (L1) has been associated with sporadic agranulocytosis, milder forms of neutropenia and other side-effects." | 3.70 | Safety profile of the oral iron chelator deferiprone: a multicentre study. ( Cohen, AR; Dipalma, A; Galanello, R; Piga, A; Tricta, F; Vullo, C, 2000) |
| " Incidence of adverse effects was comparable to that in thalassemic patients." | 2.76 | Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome. ( Cermak, J; Hochova, I; Jonasova, A; Neuwirtova, R; Siskova, M; Vondrakova, J; Walterova, L, 2011) |
| " We conclude that the short-term use of L1, with or without DFO, was safe and efficacious in our Chinese patient cohort." | 2.72 | A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. ( Chan, GC; Chik, KW; Ha, SY; Lam, CW; Lee, AC; Ling, SC; Luk, CW; Ng, IO, 2006) |
| "The rates of agranulocytosis (absolute neutrophil count [ANC] < 500 x 10(9)/L) and milder forms of neutropenia (ANC, 500-1500 x 10(9)/L) were 0." | 2.71 | Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. ( Cohen, AR; De Sanctis, V; Galanello, R; Piga, A; Tricta, F, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Totadri, S | 1 |
| Bansal, D | 1 |
| Bhatia, P | 1 |
| Attri, SV | 1 |
| Trehan, A | 1 |
| Marwaha, RK | 1 |
| Cermak, J | 1 |
| Jonasova, A | 1 |
| Vondrakova, J | 1 |
| Walterova, L | 1 |
| Hochova, I | 1 |
| Siskova, M | 1 |
| Neuwirtova, R | 1 |
| Cohen, AR | 2 |
| Galanello, R | 3 |
| Piga, A | 3 |
| De Sanctis, V | 1 |
| Tricta, F | 2 |
| Roggero, S | 1 |
| Vinciguerra, T | 1 |
| Sacchetti, L | 1 |
| Gallo, V | 1 |
| Longo, F | 1 |
| Ha, SY | 1 |
| Chik, KW | 1 |
| Ling, SC | 1 |
| Lee, AC | 1 |
| Luk, CW | 1 |
| Lam, CW | 1 |
| Ng, IO | 1 |
| Chan, GC | 1 |
| Tanner, MA | 1 |
| Dessi, C | 1 |
| Smith, GC | 1 |
| Westwood, MA | 1 |
| Agus, A | 1 |
| Roughton, M | 1 |
| Assomull, R | 1 |
| Nair, SV | 1 |
| Walker, JM | 1 |
| Pennell, DJ | 1 |
| Adhikari, D | 1 |
| Dipalma, A | 1 |
| Vullo, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Treatment With the Oral Iron Chelator Deferiprone on the Oxidative Stress of Blood Cells and on Iron Overload Status in Transfusion Dependent, Iron-overloaded Patients With Low Risk Myelodysplastic Syndrome[NCT02477631] | Phase 2 | 19 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| Iron-mediated Vascular Disease in Sickle Cell Disease.[NCT01239901] | 150 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for deferiprone and Cholera Infantum
| Article | Year |
|---|---|
Deferiprone: New insight.
Topics: Agranulocytosis; Cardiomyopathies; Clinical Trials as Topic; Deferiprone; Deferoxamine; Follow-Up St | 2005 |
4 trials available for deferiprone and Cholera Infantum
| Article | Year |
|---|---|
Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Deferiprone; Drug Therapy, Combination; Drug-Relate | 2011 |
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.
Topics: Administration, Oral; Adolescent; Adult; Agranulocytosis; Alanine Transaminase; beta-Thalassemia; Ch | 2003 |
A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Topics: Adolescent; Adult; Arthralgia; beta-Thalassemia; Biopsy, Needle; Chelation Therapy; Child; Combined | 2006 |
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Topics: Adult; Agranulocytosis; Arthralgia; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; | 2007 |
3 other studies available for deferiprone and Cholera Infantum
| Article | Year |
|---|---|
The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver I | 2015 |
Deferiprone in iron overload.
Topics: Deferiprone; Gastrointestinal Diseases; Humans; Iron Chelating Agents; Joint Diseases; Neutropenia; | 1995 |
Safety profile of the oral iron chelator deferiprone: a multicentre study.
Topics: Agranulocytosis; Alanine Transaminase; beta-Thalassemia; Deferiprone; Gastrointestinal Diseases; Hum | 2000 |